U.S. drug demand recovering with economy; Nexavar delays breast cancer in new study;

@FiercePharma: Generics, emerging markets to take over pharma growth. Story | Follow @FiercePharma

> There's new evidence that the drop in patient demand for medications during the recession is starting to reverse. Report

> Nexavar, the cancer drug sold by Onyx Pharmaceuticals and Bayer was shown to delay tumor progression in women with advanced breast cancer, according to a new study. Story

> Silenor, the new sleeping pill made by Somaxon Pharmaceuticals, is under the threat of competition from yet another generic drug maker. News

> Adverse event data show the risks of serious psychiatric side effects of Chantix, the smoking-cessation drug, were previously underestimated because Pfizer apparently failed to correctly submit hundreds of episodes to the FDA, the Institute for Safe Medicine Practices says. Article

> Shire Pharmaceuticals received an FDA warning letter stating that the company's promotional magnets advertising the attention deficit disorder drug Vyvanse are misleading. Piece

> A federal advisory panel unanimously recommended that dosing for children's acetaminophen be based primarily on the child's weight rather than age. Item

> Prostate cancer screening beginning from ages 44 to 50 may rule out the risk of dying in half of men, according to a study that showed some men may need as few as three screening tests in a lifetime. Report

Biotech News

@FierceBiotech: Canaan cashing in on Shire's $750M deal for Advanced BioHealing. Item | Follow @FierceBiotech

@JohnCFierce: Another interesting point: "More than 90 percent of recently approved cancer drugs cost more than $20,000 for a 12-week course of therapy. Follow @JohnCFierce

> Takeda wraps $13.7B Nycomed buyout, skin unit spins off. News

> Abiraterone vs. MDV3100: A prostate cancer drug showdown. Article 

> Proteomics companies create new network. News 

> Gallus Bio blueprints expansion, new hires at biologics plant. Report 

> ASCO abstracts flag new data on the hottest cancer drugs. Item

> "ASCO effect" drives up shares of troubled OXiGENE. Article 

Vaccines News

> Chongqing bids $93M for Bilthoven. Story 

> Cancer vaccine market to hit $7B by 2015. Report

> Study: HPV vax important for men. Item 

> Sanofi plots 2014 launch of new dengue vaccine. Story

> Celiac disease vax has positive Ph1 results. Article

Manufacturing News

> Golden State warning cites repeat violation. Article

> Particle detection pits man against machine. News

> Packager Amcor hears dual sustainability calls. Story 

> Pfizer's Viagra faces more counterfeit, generic attacks. News

> How GSK rose from a lonely, inventive shepherd. Report

And Finally... Stimulant medications to treat attention-deficit hyperactivity disorder are popular pills on college campuses during finals week. Story